{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:52:33Z","timestamp":1791337953275,"version":"4.3.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81703013"],"award-info":[{"award-number":["81703013"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006606","name":"Tianjin Municipal Natural Science Foundation","doi-asserted-by":"publisher","award":["23JCYBJC01730"],"award-info":[{"award-number":["23JCYBJC01730"]}],"id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.isci.2026.114824","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T15:47:40Z","timestamp":1769701660000},"page":"114824","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["SeSA-HCPT: A dual-targeting agent that induces DNA damage and inhibits repair for castration-resistant prostate cancer therapy"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2258-6404","authenticated-orcid":false,"given":"Yajie","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ShiLin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changjun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2026.114824_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.isci.2026.114824_bib2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.eururo.2018.03.028","article-title":"Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology","volume":"75","author":"Nuhn","year":"2019","journal-title":"Eur. Urol."},{"key":"10.1016\/j.isci.2026.114824_bib3","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/annonc\/mdt136","article-title":"Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)","volume":"24","author":"Loriot","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.isci.2026.114824_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114304","article-title":"Topoisomerase I inhibitors: Challenges, progress and the road ahead","volume":"236","author":"Talukdar","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.isci.2026.114824_bib5","doi-asserted-by":"crossref","first-page":"4227","DOI":"10.2147\/IJN.S377149","article-title":"Advances in Antitumor Nano-Drug Delivery Systems of 10-Hydroxycamptothecin","volume":"17","author":"Chen","year":"2022","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.isci.2026.114824_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116049","article-title":"Camptothecin structure simplification elaborated new imidazo[2,1-b]quinazoline derivative as a human topoisomerase I inhibitor with efficacy against bone cancer cells and colon adenocarcinoma","volume":"265","author":"Khodair","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.isci.2026.114824_bib7","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1200\/JCO.2009.22.1291","article-title":"Histone deacetylase inhibitors in cancer therapy","volume":"27","author":"Lane","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.114824_bib8","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41392-024-02039-0","article-title":"Epigenetics-targeted drugs: current paradigms and future challenges","volume":"9","author":"Dai","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.isci.2026.114824_bib9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrd2227","article-title":"Vorinostat","volume":"6","author":"Grant","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.isci.2026.114824_bib10","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1021\/acs.jproteome.1c00791","article-title":"An Integrative Proteome-Based Pharmacologic Characterization and Therapeutic Strategy Exploration of SAHA in Solid Malignancies","volume":"21","author":"Liu","year":"2022","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.isci.2026.114824_bib11","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S1470-2045(15)70056-2","article-title":"Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"16","author":"Krug","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.isci.2026.114824_bib12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10555-025-10253-7","article-title":"Epigenetic drugs in cancer therapy","volume":"44","author":"Suraweera","year":"2025","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.isci.2026.114824_bib13","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.bcp.2014.06.001","article-title":"A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I","volume":"90","author":"Yu","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.isci.2026.114824_bib14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1021\/ml500327q","article-title":"Discovery of Novel Multiacting Topoisomerase I\/II and Histone Deacetylase Inhibitors","volume":"6","author":"He","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.isci.2026.114824_bib15","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/j.ejmech.2017.11.021","article-title":"Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors","volume":"143","author":"Cincinelli","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.isci.2026.114824_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1010376","article-title":"A toolbox for class I HDACs reveals isoform specific roles in gene regulation and protein acetylation","volume":"18","author":"Hess","year":"2022","journal-title":"PLoS Genet."},{"key":"10.1016\/j.isci.2026.114824_bib17","doi-asserted-by":"crossref","first-page":"6599","DOI":"10.1038\/s41388-019-0897-0","article-title":"HDAC7 regulates histone 3 lysine 27 acetylation and transcriptional activity at super-enhancer-associated genes in breast cancer stem cells","volume":"38","author":"Caslini","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.isci.2026.114824_bib18","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/nm.2709","article-title":"Nuclear accumulation of HDAC4 in ATM deficiency promotes neurodegeneration in ataxia telangiectasia","volume":"18","author":"Li","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.114824_bib19","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s13402-021-00626-9","article-title":"Histone deacetylase (HDAC) 9: versatile biological functions and emerging roles in human cancer","volume":"44","author":"Yang","year":"2021","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.isci.2026.114824_bib20","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/417455a","article-title":"HDAC6 is a microtubule-associated deacetylase","volume":"417","author":"Hubbert","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.114824_bib21","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.7150\/thno.92119","article-title":"A novel selenium analog of HDACi-based twin drug induces apoptosis and cell cycle arrest via CDC25A to improve prostate cancer therapy","volume":"14","author":"Shi","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.isci.2026.114824_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2024.116957","article-title":"A novel histone deacetylase inhibitor Se-SAHA attenuates isoproterenol-induced heart failure via antioxidative stress and autophagy inhibition","volume":"487","author":"Cheng","year":"2024","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.isci.2026.114824_bib23","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.4161\/cc.7.13.6130","article-title":"A novel role of the chromokinesin Kif4A in DNA damage response","volume":"7","author":"Wu","year":"2008","journal-title":"Cell Cycle"},{"key":"10.1016\/j.isci.2026.114824_bib24","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.canlet.2022.01.002","article-title":"PHF14 knockdown causes apoptosis by inducing DNA damage and impairing the activity of the damage response complex in colorectal cancer","volume":"531","author":"Pan","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.isci.2026.114824_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16020178","article-title":"Fixed-Dose Combination Formulations in Solid Oral Drug Therapy: Advantages, Limitations, and Design Features","volume":"16","author":"Wilkins","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.isci.2026.114824_bib26","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.cancergen.2020.12.002","article-title":"DNA damaging agents and DNA repair: From carcinogenesis to cancer therapy","volume":"252\u2013253","author":"de Almeida","year":"2021","journal-title":"Cancer Genet."},{"key":"10.1016\/j.isci.2026.114824_bib27","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41392-021-00648-7","article-title":"DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.isci.2026.114824_bib28","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s40261-018-0655-z","article-title":"Efficacy and Safety of Neoadjuvant Treatment with Bevacizumab, Liposomal Doxorubicin, Cyclophosphamide and Paclitaxel Combination in Locally\/Regionally Advanced, HER2-Negative, Grade III at Premenopausal Status Breast Cancer: A Phase II Study","volume":"38","author":"Tampaki","year":"2018","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.isci.2026.114824_bib29","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1158\/2159-8290.CD-19-0582","article-title":"Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer","volume":"9","author":"Farago","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.isci.2026.114824_bib30","doi-asserted-by":"crossref","first-page":"5092","DOI":"10.1158\/1078-0432.CCR-20-1301","article-title":"A Phase I\/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer","volume":"26","author":"Pishvaian","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.114824_bib31","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/embj.201385876","article-title":"Co-regulation proteomics reveals substrates and mechanisms of APC\/C-dependent degradation","volume":"33","author":"Singh","year":"2014","journal-title":"EMBO J."},{"key":"10.1016\/j.isci.2026.114824_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/srep39787","article-title":"GPS-PAIL: prediction of lysine acetyltransferase-specific modification sites from protein sequences","volume":"6","author":"Deng","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2026.114824_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216121","article-title":"The impact of histone deacetylase inhibitors on immune cells and implications for cancer therapy","volume":"559","author":"Moran","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.isci.2026.114824_bib34","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1758-2946-3-33","article-title":"Open Babel: An open chemical toolbox","volume":"3","author":"O'Boyle","year":"2011","journal-title":"J. Cheminform."},{"key":"10.1016\/j.isci.2026.114824_bib35","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.114824_bib36","doi-asserted-by":"crossref","first-page":"D439","DOI":"10.1093\/nar\/gkab1061","article-title":"AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models","volume":"50","author":"Varadi","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.isci.2026.114824_bib37","doi-asserted-by":"crossref","first-page":"D523","DOI":"10.1093\/nar\/gkac1052","article-title":"UniProt: the Universal Protein Knowledgebase in 2023","volume":"51","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.isci.2026.114824_bib38","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226001999?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226001999?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:32:47Z","timestamp":1791336767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004226001999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2589004226001999"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2026.114824","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SeSA-HCPT: A dual-targeting agent that induces DNA damage and inhibits repair for castration-resistant prostate cancer therapy","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2026.114824","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"114824"}}